Clinical implications of warfarin interactions with five sedatives

Area of Science:

• Pharmacology and Toxicology
• Clinical Pharmacy
• Internal Medicine

Background:

• Coumarin anticoagulants, such as warfarin, are widely prescribed for thromboembolic disorders.
• Potential drug interactions can alter anticoagulant efficacy, posing risks to patient safety.
• Sedative-hypnotic drugs are frequently used, raising concerns about their interaction with coumarin therapy.

Purpose of the Study:

• To systematically investigate the anticoagulant interference of phenobarbital, secobarbital, glutethimide, chloral hydrate, and methaqualone.
• To determine the clinical significance of these interactions in patients receiving coumarin therapy.

Main Methods:

• A study involving 16 patients on stable warfarin therapy.
• Each patient served as their own control, with prothrombin times measured four times weekly.
• Investigated the effects of phenobarbital, secobarbital, glutethimide, chloral hydrate, and methaqualone administration.

Main Results:

• Phenobarbital, secobarbital, and glutethimide demonstrated significant anticoagulant inhibition.
• Chloral hydrate and methaqualone did not produce significant changes in prothrombin test results.
• Concurrent use of barbiturates/glutethimide with coumarins is decreasing.

Conclusions:

• Barbiturates and glutethimide should not be co-administered with coumarin drugs due to significant interference.
• Chloral hydrate and methaqualone exhibit pharmacologic interactions with oral anticoagulants, but these are not clinically significant.
• Chloral hydrate and methaqualone can be safely administered without increased prothrombin time monitoring during coumarin therapy.